10d
Zacks Investment Research on MSNNovo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...
3d
Zacks Investment Research on MSNNVO Stock Down 9% as CagriSema Misses Target in Second Obesity StudyNovo Nordisk NVO has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous ...
9d
GlobalData on MSNNovo Nordisk cuts Wegovy price through new direct-to-patient online pharmacyThe Danish drugmaker has launched a new online pharmacy called NovoCare Pharmacy to cut out the middlemen it so frequently ...
Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
Novo Nordisk NVO announced that it is launching ... Zacks Investment Research Image Source: Zacks Investment Research The discounted prices come on the heels of the FDA’s announcement in late ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking The ...
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...
11d
GlobalData on MSNNovo Holdings and TA Associates back BiocompositesDanish asset manager Novo Holdings, which is owned by Novo Nordisk Foundation (NNF), the majority voting shareholder of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results